Cybin Inc.

Healthcare · Biotechnology · Canada

Last price 10.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 782.47M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strat...